Trelegy Ellipta costs roughly $690 per month without insurance, and no generic version is available yet. But there are several ways to lower that cost, from a competing brand inhaler to using two separate inhalers that deliver the same three drug classes, to patient assistance programs that can bring the price to zero.
No Generic Exists Until at Least 2031
The FDA has not approved a generic version of Trelegy Ellipta. Its key patent doesn’t expire until April 2031, so a lower-cost generic copy is likely years away. That means any savings right now come from switching to a different brand, splitting the therapy across two inhalers, or using discount and assistance programs.
Breztri Aerosphere: The Closest Brand Alternative
Breztri Aerosphere is the only other single-inhaler triple therapy on the U.S. market. It contains the same three classes of medication as Trelegy (an inhaled corticosteroid, a long-acting beta agonist, and a long-acting muscarinic antagonist) but uses different active ingredients and comes as a metered-dose inhaler rather than a dry powder device.
The retail price difference is modest. Breztri lists at about $676, compared to Trelegy’s $689. That’s only a $13 gap at full price. The real savings depend on your insurance plan. Some insurers and Medicare Part D plans place one of these medications on a lower formulary tier than the other, which can mean a significantly smaller copay. It’s worth asking your pharmacist or plan administrator which triple-therapy inhaler your plan prefers before assuming the two cost the same out of pocket.
Two-Inhaler Triple Therapy
Before single-inhaler triple therapy existed, doctors prescribed the same drug combination using two devices: one inhaler containing a corticosteroid paired with a long-acting beta agonist, plus a separate inhaler for a long-acting muscarinic antagonist. This approach delivers the same medication classes as Trelegy and can cost less, especially when generics are available for one or both inhalers.
Common pairings include:
- A corticosteroid/beta agonist combo inhaler such as generic fluticasone/salmeterol (the generic of Advair) or budesonide/formoterol (Symbicort), paired with
- A standalone muscarinic antagonist inhaler such as tiotropium (Spiriva), aclidinium (Tudorza), or glycopyrrolate (Seebri)
Generic fluticasone/salmeterol is the key to making this cheaper. Because Advair’s patent has expired, its generic version can run well under $200 per month with a discount card. Add a muscarinic antagonist inhaler, and the total for both devices may still come in under the price of a single Trelegy inhaler, depending on the specific products and your pharmacy.
The trade-off is convenience. You’re managing two devices instead of one, each with its own technique and schedule. Some people find this straightforward; others are more likely to miss doses. If you’re considering this route, your prescriber can help choose a pairing that matches your condition (COPD, asthma, or both) and fits your budget.
Discount Cards and Manufacturer Coupons
If you’re paying out of pocket, pharmacy discount programs can shave some cost off the retail price. Optum Perks coupons, for example, advertise savings of up to $27 per fill on Trelegy, bringing the price down from $698 to roughly $671. That’s not dramatic, but it requires nothing more than showing a coupon at the pharmacy counter.
GSK, the company that makes Trelegy, also runs a savings program called Trelegy Savings and Support. Eligibility and the size of the discount vary, so it’s worth calling 866-475-3678 or visiting their website to see what you qualify for. Commercially insured patients often get deeper discounts through manufacturer copay cards than uninsured patients get through general coupon sites.
GSK’s Patient Assistance Program
If your income is low enough and you have no prescription drug coverage, GSK offers Trelegy at no cost through its Patient Assistance Program. The income limits are based on household size. For a single person in most U.S. states, the cutoff is $47,880 per year in gross income. For a household of two, it’s $64,920. Each additional person adds about $17,040 to the threshold. Alaska and Hawaii have slightly higher limits.
To qualify, you must live in the U.S. or Puerto Rico and have no prescription drug benefits through any insurer, including Medicaid, VA, or TriCare. Medicare Part D enrollees are not eligible for this program (though separate Medicare-specific assistance exists). If you meet the criteria, the application process involves a form that your doctor’s office can fax directly to the program along with your prescription.
Medicare Part D Coverage
If you’re on Medicare, Part D plans cover Trelegy, but how much you pay depends on your specific plan’s formulary tier and your stage of coverage. In 2026, the maximum Part D deductible is $615. After meeting that deductible, you typically pay 25% of the drug’s cost until your total out-of-pocket spending hits $2,100 for the year. Once you cross that threshold, catastrophic coverage kicks in and you pay nothing more for covered drugs for the rest of the calendar year.
For an expensive brand like Trelegy, this $2,100 annual cap is meaningful. It means your total yearly drug spending has a hard ceiling, even if the first few months of fills feel expensive. If you’re comparing plans during open enrollment, check whether Trelegy or Breztri sits on a lower tier in the plans available to you. That single difference can change your monthly copay by $50 or more.
Which Option Saves the Most?
The best path depends on your insurance situation. If you’re commercially insured, start by checking whether your plan prefers Breztri over Trelegy or vice versa, and ask about manufacturer copay cards. If you’re uninsured and meet the income limits, GSK’s patient assistance program eliminates the cost entirely. If you have Medicare Part D, the $2,100 annual out-of-pocket cap limits your exposure regardless of which brand you use.
For people paying largely out of pocket who don’t qualify for assistance, the two-inhaler approach using a generic corticosteroid/beta agonist combo plus a separate muscarinic antagonist inhaler offers the most meaningful price reduction. It requires managing two devices, but can cut the monthly cost substantially compared to any single-inhaler brand product on the market today.